ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC. has 5 Schedule 13D or 13G filings on record since 2025-08-07. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Faraday Future Intelligent Electric Inc. | 19.99% | 1,227,147 | SCHEDULE 13D/A, 2025-11-19 | 2025-11-17 |
| Alpha Capital Anstalt | 0.51% | 36,003 | SCHEDULE 13G/A, 2026-01-29 | 2026-01-28 |
Purpose of Transaction (Item 4)
Faraday Future Intelligent Electric Inc.
The Reporting Person is filing this First Amendment to report that it has acquired beneficial ownership of shares of Common Stock issuable upon the conversion of shares of Series B Preferred Stock that were purchased pursuant to the Subscription Agreement but which were not convertible until the receipt of the approval of the Issuer's stockholders, which approval was obtained on November 12, 2025, as reported on the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 17, 2025. The Reporting Person may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Person also entered into a Lead Investor Agreement with the Issuer on September 19, 2025, pursuant to which the Issuer agreed to appoint members of its board of directors and certain officers designated by the Reporting Person upon the closing of the transactions contemplated by the Subscription Agreement (the "Lead Investor Agreement"). A copy of the Lead Investor Agreement was filed with the Original Schedule 13D as Exhibit 2. The Reporting Person intends to review its investment in the Issuer on a continuing basis and may decide at any time to increase the size of its investment in the Issuer in the open market, in …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-19; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Alpha Capital Anstalt | 2.22% | SCHEDULE 13G/A |
| 2025-11-12 | Alpha Capital Anstalt | 9.06% | SCHEDULE 13G/A |
| 2025-11-12 | Faraday Future Intelligent Electric Inc. | 8% | SCHEDULE 13D |
| 2025-11-19 | Faraday Future Intelligent Electric Inc. | 19.99% | SCHEDULE 13D/A |
| 2026-01-29 | Alpha Capital Anstalt | 0.51% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for ALXCRYPTO HOLDINGS, INC. f/k/a QUALIGEN THERAPEUTICS, INC.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.